Evidence map›Paper›PMID 37296082›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2023

Baseline neuropsychiatric symptoms and psychotropic medication use midway through data collection of the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) cohort.

Angelina J Polsinelli, Ryan J Wonderlin, Dustin B Hammers, Alex Pena Garcia, Ani Eloyan, Alexander Taurone, Maryanne Thangarajah, Laurel Beckett, Sujuan Gao, Sophia Wang and 42 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

52 authors.

Angelina J PolsinelliDepartment of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Ryan J WonderlinMarian University College of Osteopathic Medicine, Indianapolis, Indiana, USA.
Dustin B HammersDepartment of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Alex Pena GarciaMarian University College of Osteopathic Medicine, Indianapolis, Indiana, USA.
Ani EloyanDepartment of Biostatistics, Center for Statistical Sciences, Brown University, Providence, Rhode Island, USA.
Alexander TauroneDepartment of Biostatistics, Center for Statistical Sciences, Brown University, Providence, Rhode Island, USA.
Maryanne ThangarajahDepartment of Biostatistics, Center for Statistical Sciences, Brown University, Providence, Rhode Island, USA.
Laurel BeckettDepartment of Public Health Sciences, University of California - Davis, Davis, California, USA.
Sujuan GaoDepartment of Biostatistics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Sophia WangDepartment of Psychiatry, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Kala KirbyDepartment of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Paige E LoganDepartment of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Paul AisenAlzheimer's Therapeutic Research Institute, University of Southern California, San Diego, California, USA.
Jeffrey L DageDepartment of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Tatiana ForoudDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Percy GriffinMedical & Scientific Relations Division, Alzheimer's Association, Chicago, Illinois, USA.
Leonardo IaccarinoDepartment of Neurology, University of California - San Francisco, San Francisco, California, USA.
Joel H KramerDepartment of Neurology, University of California - San Francisco, San Francisco, California, USA.
Robert KoeppeDepartment of Radiology, University of Michigan, Ann Arbor, Michigan, USA.
Walter A KukullDepartment of Epidemiology, University of Washington, Seattle, Washington, USA.
Renaud La JoieDepartment of Neurology, University of California - San Francisco, San Francisco, California, USA.
Nidhi S MundadaDepartment of Neurology, University of California - San Francisco, San Francisco, California, USA.
Melissa E MurrayDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Kelly NudelmanDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
David N Soleimani-MeigooniDepartment of Neurology, University of California - San Francisco, San Francisco, California, USA.
Malia RumbaughDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Arthur W TogaLaboratory of Neuro Imaging, USC Stevens Neuroimaging and Informatics Institute, Keck School of Medicine of USC, Los Angeles, California, USA.
Alexandra TouroutoglouDepartment of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Prashanthi VemuriDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Alireza AtriBanner Sun Health Research Institute, Sun City, Arizona, USA.
Gregory S DayDepartment of Neurology, Mayo Clinic, Jacksonville, Florida, USA.
Ranjan DuaraWien Center for Alzheimer's Disease and Memory Disorders, Mount Sinai Medical Center, Miami, Florida, USA.
Neill R Graff-RadfordDepartment of Neurology, Mayo Clinic, Jacksonville, Florida, USA.
Lawrence S HonigTaub Institute and Department of Neurology, Columbia University Irving Medical Center, New York, New York, USA.
David T JonesDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Joseph MasdeuNantz National Alzheimer Center, Houston Methodist and Weill Cornell Medicine, Houston, Texas, USA.
Mario F MendezDepartment of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Kyle WomackDepartment of Neurology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.
Erik MusiekDepartment of Neurology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.
Chiadi U OnyikeDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Meghan RiddleDepartment of Psychiatry, Alpert Medical School, Brown University, Providence, Rhode Island, USA.
Emily RogalskiDepartment of Psychiatry and Behavioral Sciences, Mesulam Center for Cognitive Neurology and Alzheimer's Disease, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Steven SallowayDepartment of Psychiatry, Alpert Medical School, Brown University, Providence, Rhode Island, USA.
Sharon J ShaDepartment of Neurology & Neurological Sciences, Stanford University, Palo Alto, California, USA.
Raymond S TurnerDepartment of Neurology, Georgetown University, Washington D.C., USA.
Thomas S WingoDepartment of Neurology and Human Genetics, Emory University School of Medicine, Atlanta, Georgia, USA.
David A WolkDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Maria C CarrilloMedical & Scientific Relations Division, Alzheimer's Association, Chicago, Illinois, USA.
Bradford C DickersonDepartment of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Gil D RabinoviciDepartment of Neurology, University of California - San Francisco, San Francisco, California, USA.
Liana G ApostolovaAlzheimer's Therapeutic Research Institute, University of Southern California, San Diego, California, USA.
LEADS ConsortiumDepartment of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.

Funding

National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD)U24AG021886 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI TATIANA M. FOROUD · 2002 to 2026
$119.8M
Early Onset AD Consortium - the LEAD Study (LEADS)U01AG057195 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI APOSTOLOVA, LIANA G, CARRILLO, MARIA C · 2018 to 2023
$70.3M
National Alzheimer's Coordinating CenterU24AG072122 · NIA · UNIVERSITY OF WASHINGTON · PI STEPHENS, KARI A · 2021 to 2025
$45.8M
Research Education ComponentP30AG010133 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI GHETTI, BERNARDINO FRANCESCO · 1991 to 2020
$37.3M
Research Education ComponentP30AG062422 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Gil Dan Rabinovici · 2019 to 2026
$36.9M
Research Education ComponentP30AG062421 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI STEVEN E ARNOLD · 2019 to 2026
$36.5M
Research Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI NILUFER ERTEKIN-TANER · 2019 to 2026
$33.5M
Research Education CoreP30AG066462 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Miguel Arce · 2020 to 2026
$30.1M
Research Education ComponentP30AG066507 · NIA · JOHNS HOPKINS UNIVERSITY · PI MARILYN S. ALBERT · 2020 to 2026
$29.3M
The Goizueta Alzheimer's Disease Research CenterP30AG066511 · NIA · EMORY UNIVERSITY · PI Amy D Rodriguez · 2020 to 2026
$29.0M
Stanford Alzheimer's Disease Research CenterAdmin Supp: Developing iPSC models for AD and PDP30AG066515 · NIA · STANFORD UNIVERSITY · PI ELIZABETH MORMINO · 2020 to 2026
$29.0M
Research Education ComponentP30AG066444 · NIA · WASHINGTON UNIVERSITY · PI DAVID M. HOLTZMAN · 2020 to 2026
$28.7M
NIA NIH HHS P30 AG010133NIA NIH HHS P30 AG062421NIA NIH HHS P30 AG062422NIA NIH HHS P30 AG062677NIA NIH HHS P30 AG066444NIA NIH HHS P30 AG066462NIA NIH HHS P30 AG066506NIA NIH HHS P30 AG066507NIA NIH HHS P30 AG066511NIA NIH HHS P30 AG066515NIA NIH HHS P30 AG066530NIA NIH HHS P30 AG072976NIA NIH HHS P30 AG072977NIA NIH HHS P30 AG072979NIA NIH HHS P30 AG072980NIA NIH HHS R01 AG057739NIA NIH HHS R37 AG057739NIA NIH HHS R56 AG057195NIA NIH HHS R56AG057195NIA NIH HHS U01 AG057195NIA NIH HHS U01AG057195NIA NIH HHS U24 AG021886NIA NIH HHS U24AG021886NIA NIH HHS U24 AG072122NIDCD NIH HHS K23 DC016912
6 · The paper itself

Abstract

introductionWe examined neuropsychiatric symptoms (NPS) and psychotropic medication use in a large sample of individuals with early-onset Alzheimer's disease (EOAD; onset 40-64 years) at the midway point of data collection for the Longitudinal Early-onset Alzheimer's Disease Study (LEADS).

methodsBaseline NPS (Neuropsychiatric Inventory - Questionnaire; Geriatric Depression Scale) and psychotropic medication use from 282 participants enrolled in LEADS were compared across diagnostic groups - amyloid-positive EOAD (n = 212) and amyloid negative early-onset non-Alzheimer's disease (EOnonAD; n = 70).

resultsAffective behaviors were the most common NPS in EOAD at similar frequencies to EOnonAD. Tension and impulse control behaviors were more common in EOnonAD. A minority of participants were using psychotropic medications, and use was higher in EOnonAD. DISCUSSION: Overall NPS burden and psychotropic medication use were higher in EOnonAD than EOAD participants. Future research will investigate moderators and etiological drivers of NPS, and NPS differences in EOAD versus late-onset AD.

Indexed as

Alzheimer DiseaseAgedData CollectionHumansLongitudinal Studiesearly-onset Alzheimer's diseaseearly-onset dementiamild cognitive impairmentneuropharmacologyneuropsychiatric symptomspsychotropic medications

Identifiers

PMID37296082
PMCPMC10709525

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.